Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IOL Myopia, Hyperopia Studies Should Include 3-Year Follow Up - FDA Panel

This article was originally published in The Gray Sheet

Executive Summary

Intraocular lens manufacturers pursuing approval for myopia and hyperopia indications should conduct 550-patient studies with three-year follow up, FDA's Ophthalmic Devices Advisory Panel concluded at an Oct. 23 meeting in Silver Spring, Maryland.

You may also be interested in...

Separate Phakic IOL Trials Recommended For Young, Old Patients

Refractive implant manufacturers pursuing claims for device implantation in phakic eyes - those with a natural lens - should conduct separate studies on younger and older patient populations to examine the risk of cataractogenesis, FDA's Ophthalmic Devices Advisory Panel recommended at a May 12 meeting.

Biogen’s Recipe For Success In Knowledge Management

Biogen’s “recipe-driven qualification” knowledge management program standardizes data collection and reporting in the laboratory, with efficiency gains of 66%.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts